|20.33||+0.7850||+4.02%||Vol 6.95M||1Y Perf -|
|Oct 4th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||26.75||Analyst Rating||Strong Buy 1.49|
|Potential %||31.58||Finscreener Ranking||★★★ 50.01|
|Insiders Trans % 3/6/12 mo.||-50/-50/-20||Value Ranking||★ 39.51|
|Insiders Value % 3/6/12 mo.||42/42/54||Growth Ranking||★+ 42.85|
|Insiders Shares Cnt. % 3/6/12 mo.||40/40/49||Income Ranking||— -|
|Price Range Ratio 52W %||50.63||Earnings Rating||Strong Sell|
|Market Cap||3.07B||Earnings Date||14th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||14th Nov 2023|
|Estimated EPS Next Report||0.09|
|EPS Growth Next 5 Years %||50.30|
|Avg. Weekly Volume||1.09M|
|Avg. Monthly Volume||0|
|Avg. Quarterly Volume||3.30M|
Array BioPharma Inc. (NASDAQ: ARRY) stock closed at 11.3 per share at the end of the most recent trading day (a 3.59% change compared to the prior day closing price) with a volume of 4.04M shares and market capitalization of 3.07B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs people. Array BioPharma Inc. CEO is .
The one-year performance of Array BioPharma Inc. stock is %, while year-to-date (YTD) performance is 72.96%. ARRY stock has a five-year performance of 29.78%. Its 52-week range is between 13.86 and 26.64, which gives ARRY stock a 52-week price range ratio of 50.63%
Array BioPharma Inc. currently has a PE ratio of -45.70, a price-to-book (PB) ratio of 45.62, a price-to-sale (PS) ratio of 2.37, a price to cashflow ratio of 60.70, a PEG ratio of -0.91, a ROA of -4.67%, a ROC of -6.35% and a ROE of -160.74%. The company’s profit margin is 1.10%, its EBITDA margin is 5.30%, and its revenue ttm is $1.24 Billion , which makes it $8.21 revenue per share.
Of the last four earnings reports from Array BioPharma Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.09 for the next earnings report. Array BioPharma Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Array BioPharma Inc. is Strong Buy (1.49), with a target price of $26.75, which is +31.58% compared to the current price. The earnings rating for Array BioPharma Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Array BioPharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Array BioPharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 62.62, ATR14 : 1.02, CCI20 : 1.69, Chaikin Money Flow : 0.14, MACD : 0.00, Money Flow Index : 55.84, ROC : 10.78, RSI : 0.00, STOCH (14,3) : 35.59, STOCH RSI : 0.00, UO : 48.37, Williams %R : -64.41), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Array BioPharma Inc. in the last 12-months were: Patel Nipul (Sold 54 593 shares of value $1 262 190 )
Mon, 14 Aug 2023 02:25 GMT Array Technologies (ARRY) Gets a Buy from Truist Financial- TipRanks. All rights reserved.
Wed, 09 Aug 2023 13:40 GMT Unusually active option classes on open August 9th- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.